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Abstract
CircRNAs are a novel type of RNAs. With the newly developed technology of next-generation sequencing (NGS),
especially RNA-seq technology, over 30,000 circRNAs have already been found. Owing to their unique structure,
they are more stable than linear RNAs. CircRNAs play important roles in the carcinogenesis of cancer. The
expression of circRNAs is correlated with patients’ clinical characteristics, and circRNAs play a vital role in many
aspects of malignant phenotypes, including cell cycle, apoptosis, vascularization, and invasion; metastasis as a RNA
sponge, binding to RBP; or translation. Therefore, it is meaningful to further study the mechanism of interactions
between circRNAs and tumors. The role of circRNAs as molecular markers or potential targets will provide
promising application perspectives, such as early tumor diagnosis, therapeutic evaluation, prognosis prediction, and
even gene therapy for tumors.
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Background
Circular RNAs (circRNAs) are a large group of RNAs
that form covalently closed continuous loops. The first
circRNA was found in a RNA virus in 1976 [1, 2]. Not
long after that, Hsu MT et al. discovered the existence
of a circular form of RNA in the cytoplasm of monkey
renal CV-1 cells using electron microscopy [3]. In 1996,
circRNAs were found to consist of exons from RNA
transcripts in human cells [4]. In recent years, an in-
creasing number of circRNAs have been found owing to
the development of sequencing technologies, with the
RNA-seq technology of next-generation sequencing be-
ing the most notable. To date, the total number of
known circRNAs has reached up to 30,000.
CircRNAs have long been regarded as an accidental
byproduct, resulting from errors during post-transcriptional
processing, and recent studies have found important func-
tions of circRNAs in multiple biological processes [5]. Cir-
cRNAs can act in a broad range of roles, including as
miRNA sponges [6] and regulators of RNA binding protein
(RBP) in modulating the expression of protein-encoding
genes [7]. Some circRNAs even encode peptides [8]. Thus,
circRNA disorders should influence the development of a
variety of human diseases, including cancer [9]. Further-
more, the unique structures of circRNAs lead to their in-
sensitivity to ribonucleases. Thus, unlike linear RNAs,
circRNA molecules can exist in tissues, serum, and urine.
Owing to this characteristic, the discovery of circRNAs as
biomarkers for human cancer has been shown to be a tre-
mendous possibility.
Biogenesis of circRNAs
CircRNAs can be sorted into three types, including ex-
onic circRNAs, intronic circRNAs, and retained-intron
circRNAs, which are produced from different cycling
mechanisms. During the formation of circRNAs, specific
sequences are conserved and sequences from upstream
and downstream regions are linked together in a reverse
direction, all of which contribute to mature circRNAs by
back splicing [10]. Although the efficiency of back spli-
cing is much lower than in linear RNAs [5], there is still
a large intracellular abundance of circRNAs due to their
stability and relatively long half-life period [11]. The
earliest back splicing mechanism is dependent on com-
plementary intron matches [12], which widely exist in
the exonic circRNA formation process. CircRNAs st-
ructured from this mechanism have special repeated
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sequences, such as Alu and other short sequences, on
their two sides [13, 14]. After transcription into RNA
precursors, the exon sequences on the two sides of the
cycling region will complementarily match with each
other under the promotion of repetitive sequences, such
as Alu, to form a circle shape. Following this, the spli-
ceosome binds to the cycled RNA precursor under the
effect of U6 and U2. Then, it selectively cuts out the
exon in the cycling region by cooperating with the pro-
tein complex and the U5 core [15, 16]. At the same time,
exon sequences connection are reversely cut, forming
mature circRNA.
The mechanism of intronic circRNA formation is differ-
ent from that of exonic circRNA. The formation of intronic
circRNAs relies on GU-rich sequences near the 5′ splice
site and C-rich sequences near the branch point. During
the back splicing process, the two segments bind into a cir-
cle first. Then exonic sequences and intronic sequences in
the binding part are cut out by the spliceosome. The
remaining introns are eventually pieced together to form
mature circRNA [17, 18]. Recently, Li et al. found another
novel type of circRNA consisting of both exons and introns
that overexpress themselves according to their comple-
mentary sequences [7]; however, the exact splicing mech-
anism has yet to be determined (Fig. 1a).
Similar to linear RNA, the biogenesis of circRNAs is
regulated by various types of proteins, such as the RNA
spliceosome and RNA binding protein (RBP). The RNA
spliceosome and spicing process are vital research fron-
tiers in biomedicine. The RNA spliceosome is a RNA-
based enzyme with a U5 core consisting of 5 snRNAs
and a number of proteins. Under the effect the U6 and
U2 promoters, many proteins cooperatively process pre-
RNAs [16]. Similar to mRNA formation, circRNAs can
be spliced from linear RNA precursors by the spliceo-
some. Furthermore, one linear RNA molecule can be
processed into different types of RNAs, including
mRNA, circRNA, and lncRNA, through different spli-
cing events. For example, HIPK3 pre-mRNA can be
spliced into HIPK3 mRNA and its second exon can also
form circRNA hsa_circ_0018082 [13]. There is also a
competition between inverted splicing of circRNA,
mRNA, and lncRNA during splicing [19], which may be
a regulation mechanism of circRNAs. Another regulated
protein is the Quaking (QKI) protein, a representative
molecule. It can bind to specific downstream sites on
the linear pre mRNA sequence and promote cycling and
inverted splicing of circRNAs [20] (Fig. 1b).
Databases of circRNAs
With the application of next-generation sequencing and
bioinformatics, many circRNAs are being discovered
and integrated into the circRNA database [9] (Table 1).
The Cirbase and Deepbase 2.0 databases contain over
150,000 circRNA genomes and mature RNA sequences
of different species, including human, fruit fly, and
nematode [21–23]. The Cir2Traits database contains
circRNAs relating to various diseases [24]. Circnet and
circRNAbase contain alternatively spliced variants and
their expression patterns in different tissues and pos-
sible miRNA regulated networks [21, 25]. The CircIn-
teractome database contains corresponding genome
sequences, primers for qRT-PCR, and siRNAs of ma-
ture circRNAs. It can also be used to predict RBP bind-
ing sites [26]. The CIRCpedia and TSCD databases
contain RNA-seq data of several human cell lines and
samples [27, 28].
CircRNAs can be a novel biomarker in cancer
Unlike linear RNA, 3′ and 5′ terminals are not exposed
in circRNAs; thus, they are not sensitive to ribonucle-
ases, such as exonuclease or RNase R and have a longer
half-life period with a more prominent specificity in hist-
ology and pathology [29]. Meanwhile, circRNAs are
easier to extract and detect with higher specificity com-
pared with proteins; thus, circRNAs are an ideal molecu-
lar marker for cancer. With the application of RNA-seq
[12, 30], changes in the expression of circRNAs are
found to be prevalent in many cancers, including
esophageal cancer [31], glioma [32], and hepatocellular
carcinoma [33]. Further experiments and analysis on
clinical files confirm that the expression levels of some
circRNAs vary according to TNM stage, metastasis, and
size the of tumor in esophageal cancer [34], hepatocellu-
lar carcinoma [35, 36], and colorectal cancer [37]. Free
circRNA molecules are degraded in the extracellular en-
vironment, but studies show that circRNAs that are pro-
duced intracellularly can be secreted to the exterior of
an exosome and be restored after an extended period of
time. Li et al. found high expression of circ_0001649 in
patients with liver cancer through RNA sequencing and
qRT-PCR, and the expression level in the exosome is
closely related to clinical characteristics, such as tumor
size [33] (Table 2).
Because of their unique structure, circRNAs are more
stable in tissues, serum, savory, or urine compared with
circulating tumor DNAs (ctDNAs) or linear RNAs.
There is also a greater possibility to screen for sensitive
and specific molecular biomarkers from thousands of
circRNAs with regard to the relatively small number of
miRNAs. Testing circRNAs by RT-PCR and in-situ
hybridization is also more specific and sensitive than
detecting proteins by an antigen-antibody reaction. In
conclusion, the use of circRNAs outweighs the use of
current tumor biomarkers in many fields, and they
could be promising molecular biomarkers and new tar-
gets for future drugs.
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The function of circRNAs in human cancer
CircRNAs are widely involved in physiological and patho-
logical processes, and studies have found that circRNAs
can be involved in biological activities by acting as a
miRNA sponge [6], binding RBPs [7], and translating pep-
tides [8, 38]. Of these, the role of circRNAs as a miRNA
sponge is the main mechanism of circRNAs in tumor
cells. There are many miRNA binding sites on circRNAs.
Thus, circRNAs can bind to miRNA as a RNA sponge
and can regulate miRNA and downstream gene expres-
sion through a ceRNA mechanism and contribute to
tumor progression. The following examples present
current studies on circRNAs and their functions in human
cancer.
ciRS-7
ciRS-7, also called CDT1as, is one of the earliest known
circRNAs and regulates miRNA in tumor cells [39].
ciRS-7 is spliced from the antisense transcript of the
CDR1 gene. It was first found to be upregulated in ma-
lignant tumor cell lines, such as HeLa cells, and further
studies found more than seventy miRNA binding sites in
Fig. 1 The biogenesis of circRNAs. a Alternative splicing of an RNA precursor. A linear RNA precursor can be cis-spliced into linear RNA, including mRNA
and lncRNA. Special sequences, such as Alu, in the RNA precursor can combine to form a cycle and lead the spliceosome to produce different types of
circRNAs through back splicing. b Different circRNAs have different back splicing mechanisms. Exonic circRNAs have cycling sequences, such as the Alu
sequence, on the two sides. The two sequences bind to each other complementarily and are then spliced by the spliceosome, which consists of U2 and
U6. Intronic circRNAs form a cycle through the combination of upstream introns of the GU rich sequence and the downstream C rich sequence, and they
are spliced by spliceosome
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ciRS-7 [40]. Later, it was discovered that ciRS-7 can bind
to miR7 as a miRNA sponge to downregulate miR-7 ex-
pression [41]. miR-671 was found to be another binding
site, and the combination of the two molecules mediates
the Ago2-mediated cleavage of ciRS-7 to release the
absorbed miR-7 [42, 43]. This suggests that miR-671 di-
minishes the inhibition of miR-7 expression through
ciRS-7; improves the miR7 level in tumor cells; contrib-
utes to the increase of downstream target oncogenes,
such as EGFR and XIAP; and promotes vascularization,
metastasis and reproduction of tumor cells [41, 44].
circ-Foxo3
Despite encoding for Foxo3, the Foxo3 gene can encode
for two noncoding RNAs, the pseudogene FOXO3P and
circ-Foxo3. Yang et al. found that the two RNAs can
both act as miRNA sponges for miR-22, miR-136*, miR-
138, miR-149*, miR-433, miR-762, miR-3614-5p, and
miR-3622b-5p, influencing their function by binding to
them. Thus, they are involved in the progression of
tumors [45]. Studies have shown that FOXO3P, circ-
Foxo3, and Foxo3 mRNA expressed elsewhere can in-
hibit the growth of a tumor. Further studies have found
high levels of circ-Foxo3 in normal cells and that it
binds to p21 and CDK2 to form a circ-Foxo3-p21-CDK2
tripolymer. Thus, in this way, the function of CDK2 is
restricted, leading to a decrease in cell proliferation, and
the silencing of circ-Foxp3 will contribute to much faster
growth in malignant tumor cells [46].
Hsa_circ_001569
Hsa_circ_001569 is a circRNA of 1776 bp that is spliced
by linear a RNA precursor from the ABCC1 gene. The
official name of hsa_circ_001569 is hsa_circ_0000677.
Liang et al. found that the hsa_circ_001569 had signifi-
cantly high expression in colorectal cancer tissue and
that it correlated positively with the degree of clinical
features, such as the TNM stage [37]. This means hsa_-
circ_001569 may be closely related to colorectal cancer
progression. Another study later confirmed this, and hsa_-
circ_001569 can act as a sponge to bind to miR-145 and
inhibit the transcriptional activity of miR-145 without in-
fluencing its expression level. Thus, has_circ_001569 leads
to the upregulation of target genes of miR-145, including
E2F5, BAG4, and FMNL2, and acts as a positive regulator
in cell proliferation and invasion of colorectal cancer.
Table 1 Databases of circRNAs
Database Developers Functions of database Most recent
version
Address Reference
circRNABase Li J et al. Constructing a network of predicted
interactions between miRNAs circular




circBase Glazar P et al. Providing merged and unified data sets
of circRNAs and the evidence supporting
their expression
December 2015 http://www.circbase.org/ [22]
deepBase v2.0 Zheng L et al. Annotating 14867 human circRNAs. November 2015 http://deepbase.sysu.edu.cn/ [23]
Circ2Traits Ghosal S et al. Constructing a network of predicted
interactions between miRNAs and protein
coding, long non-coding and circular RNA
genes. Disease associated SNPs were
mapped on circRNA loci, and Argonaute
(Ago) interaction sites on circular RNAs
were identified
December 2013 http://gyanxet-beta.com/circdb/ [24]
circNet Liu Y et al. Providing novel circRNAs, integrated
miRNA-target networks, expression
profiles of circRNA isoforms, genomic
annotations of circRNA isoforms and
sequences of circRNA isoforms
December 2015 http://circnet.mbc.nctu.edu.tw/ [25]
CircInteractome Dudekula DB
et al.
Identifying potential circRNAs that can
act as RBP sponges; design junction-
spanning primers for specific detection
of circRNAs of interest; design siRNAs for
circRNA silencing, and Identify potential
internal ribosomal entry sites (IRES).
December 2015 https://circinteractome.nia.nih.gov/ [26]
CIRCpedia Yang L et al. Containing circRNA back-splicing and





TSCD He C et al. Depositing the features of tissue specific
circRNAs in the human and mouse genomes.
August 2016 http://gb.whu.edu.cn/TSCD/ [28]
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circHIPK3
circHIPK3 is produced by the second exon of the HIPK3
gene. Huang found higher circRNA levels, including cir-
cHIPK3, by RNA sequencing seven types of tumor sam-
ples and six types of normal tissues [13]. Silencing
circHIPK3 relieves the proliferation speed of tumor cells.
Further studies found that circHIPK3 binds to eighteen
sites of nine miRNAs. It was found that circHIPK3 in-
hibits miR-124 activity by working as the sponge of miR-
124; thus, it can influence the proliferation of tumor
cells through genes, including iASPP [47].
Fusion-circRNAs
The genomes of tumor cells are unstable; thus, many
chromosome translocations exist, especially in lymph-
oma. Gene fusions may lead to incorrectly spliced
mRNAs, during which circRNA (fusion-circRNA,f-cir-
cRNA) comes into being. For example, the PML/RARa
and MLL genes fused and produced f-circM9 and f-circPR
and knockouts of f-circM9 and f-circPR lead to apoptosis
of a large amount of tumor cells as well as increases their
sensitivity to drugs, such as arsenic [48]. Together, these
results suggest that f-circM9 and f-circPR play important
roles in hematological malignancy.
cZNF292
Silencing cZNF292 in human endothelium cells will in-
hibit the tube formation process these cells undergo
[49]. cZNF292 also exists in glioma cells [50]. Downreg-
ulation of cZNF292 inhibits the proliferation and
vascularization of glioma cells and reduces the levels of
cellular Cyclin A, CDK2, p-CDK2, β-catenin, p-STAT3
(Tyr705) and p-STAT5 (Tyr694). Thus, the cells are
arrested in the G2/M phase due to modifications in the
functioning of the Wnt/β-catenin pathway. Meanwhile,
it was found that downregulation of cZNF292 contrib-
utes to decreased transcription of E2F1, NF-κB, Sp1,
HIF-1, AP-1, STAT3, and STAT5, thus inhibiting tube
formation of tumor cells. However, studies show that
cZNF292 does not function as a RNA sponge, and the
mechanism requires further study [49].
circTCF25
In 467 samples of carcinomas of the urinary bladder,
Zhang et al. detected circRNAs with prominent differen-
tial expression through microarray analysis. It was con-
firmed by qRT-PCR that six circRNAs, including
circTCF25 (hsa_circ_0041103), were highly expressed in
tumor tissues. Another study demonstrated that
circTCF25 can upregulate the levels of CDK6 by working
as a RNA sponge for miR-103a-3p and miR-107. Thus,
it promotes the proliferation and metastasis of urinary
bladder carcinoma [51].
Prospect
CircRNAs are novel molecules that have been discov-
ered in recent years. They are no longer recognized as
products of transcription errors. On the contrary, they
have become a popular research subject, after miRNAs
and lncRNAs, owing to their important functions [52–
56]. The formation of a mature circRNA molecule has at
least two mechanisms, which are different from selective
splicing in linear RNAs; however, the detailed molecular
mechanism requires further studies. There may be a
third mechanism involving the formation of retained-
intron circRNAs that contain both exons and introns,
and this has also yet to be explored. Moreover, different
types of proteins and miRNAs have been found to take
part in the processing of pre-RNAs to circRNAs. The
mechanism of circRNAs formation has yet to be discov-
ered, and it remains an attractive mystery.
A tremendous amount of data indicate that circRNAs
regulate other genes at the transcriptional and post-
transcriptional levels. Some can even encode proteins
directly and are thus involved in physiological and
pathological processes, including influencing malignant
tumors. Until now, the miRNA sponge has been found
to be a possible mechanism for circRNA function. They
can specifically bind to miRNAs and regulate gene ex-
pression by competing with competing endogenous
RNA (ceRNA), including lncRNAs, mRNAs, and pseu-
dogenes. The participation of circRNAs in the ceRNA
network renders it more complete and complex. Cir-
cRNAs compete with mRNAs from the same preRNAs
during the splicing process, and circRNAs were recently
found to encode for proteins. This demonstrates their
involvement in biological procedures, provides a more
complete understanding of the RNA language, and en-
riches the central dogma [57–59]. Knowledge of cir-
cRNAs still remains at a superficial level, and more
functions remain to be discovered among over 30,000
molecules, as only a limited number of reports describe
their functions. Exploration of their functions will bring
humans closer to the essence of life.
CircRNAs are much more stable compared to linear
RNAs owing to their unique structure. With regard
to biological markers of cancer, circRNAs have dem-
onstrated their wide perspective. Studies have already
found differential expression of circRNAs in tissues
and blood, and their expression differs from those of
miRNA and lncRNA [60–62]. It is possible to build a
model for prognosis by combining them with various
other biomarkers and thus improve the accuracy and
specificity of diagnosis. The clinical applications of
circRNAs continues to expand, with their use in sam-
ples, such as saliva and urine, and research on cir-
cRNAs is indeed a very promising aspect of the study
of life sciences.
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Previous studies have reported that circRNAs are one
type of molecular marker in tumors and that they can
influence apoptosis and infiltration. CircRNAs are po-
tential targets for new drugs. For example, the fusion-
circRNA found in leukemia is associated with chemo-
therapy resistance, and knocking out expression of f-
circM9 can lead to apoptosis of leukemia cells and de-
crease its drug resistance to Ara-C [48]. On the other
hand, circRNAs perform their functions by mediating
miRNAs through a miRNA sponge. This process can
also act as a treatment target for malignant tumors. It
was also revealed that circRNAs can encode multiple
peptides, which can also be used to treat tumors. How-
ever, more progress needs to be made between circ-RNA
and tumor treatment since the process to effectively and
efficiently transform circRNAs into targeted cells is still
a major problem that needs to be solved. Although
nanoparticles have been applied as transforming vehicles
in gene therapy and the Synergistic Photodynamic/
Photothermal/Chemotherapy of Cancer drug releasing
system has also made some advancement, neither have
been utilized in clinical practice. Further studies are still
needed to reach a definite resolution.
Conclusions
In conclusion, current achievements in the study of cir-
cRNAs and their functions are still very limited. To our
excitement, this mystery will eventually be solved through
scientists’ endeavors and applications of new methods and
techniques. CircRNAs function in an increasingly signifi-
cant way in the diagnosis and therapy of cancers and will
provide precise strategies for affecting human cancers.
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